Antiviral researchCytomegalovirusDrug ResistanceViralHumansAntiviral Agents
A new locus of foscarnet resistance in the cytomegalovirus UL54 DNA polymerase gene among uncharacterized mutations in recent clinical trials.
Sunwen Chou, Alexis Minyard, Justin Watanabe
Published: 202610.1016/j.antiviral.2025.106340
Abstract
In two recent Phase 3 clinical trials of maribavir that also involved existing standard therapies, many uncharacterized cytomegalovirus UL54 DNA polymerase genetic variants were encountered. Six UL54 mutations were selected for phenotyping, based on…
Preview only. Read the full abstract at the source